FR3008978A1 - "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" - Google Patents

"nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" Download PDF

Info

Publication number
FR3008978A1
FR3008978A1 FR1357277A FR1357277A FR3008978A1 FR 3008978 A1 FR3008978 A1 FR 3008978A1 FR 1357277 A FR1357277 A FR 1357277A FR 1357277 A FR1357277 A FR 1357277A FR 3008978 A1 FR3008978 A1 FR 3008978A1
Authority
FR
France
Prior art keywords
compound
methyl
preparation
mmol
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR1357277A
Other languages
English (en)
French (fr)
Inventor
Patrick Casara
Diguarher Thierry Le
Jean-Michel Henlin
Jerome-Benoit Starck
Tiran Arnaud Le
Nanteuil Guillaume De
Olivier Geneste
James Edward Paul Davidson
James Brooke Murray
I-Jen Chen
Claire Walmsley
Christopher John Graham
Stuart Ray
Daniel Maddox
Simon Bedford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Vernalis R&D Ltd
Original Assignee
Les Laboratoires Servier SAS
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS, Vernalis R&D Ltd filed Critical Les Laboratoires Servier SAS
Priority to FR1357277A priority Critical patent/FR3008978A1/fr
Priority to UY35653A priority patent/UY35653A/es
Priority to ARP140102679A priority patent/AR099914A1/es
Priority to EP16201228.0A priority patent/EP3168217A1/fr
Priority to EP14758604.4A priority patent/EP3027602B1/fr
Priority to HK16106759.0A priority patent/HK1218753A1/zh
Priority to BR112016001333-6A priority patent/BR112016001333B1/pt
Priority to DK14758604.4T priority patent/DK3027602T3/en
Priority to SI201430784T priority patent/SI3027602T1/en
Priority to CA2917965A priority patent/CA2917965C/fr
Priority to PL14758604T priority patent/PL3027602T3/pl
Priority to RU2016106002A priority patent/RU2693404C2/ru
Priority to RS20180839A priority patent/RS57545B1/sr
Priority to SG11201600004SA priority patent/SG11201600004SA/en
Priority to HUE14758604A priority patent/HUE039507T2/hu
Priority to CN201480041559.7A priority patent/CN105408321B/zh
Priority to AU2014294866A priority patent/AU2014294866B2/en
Priority to MX2016000900A priority patent/MX364479B/es
Priority to PT147586044T priority patent/PT3027602T/pt
Priority to PCT/FR2014/051884 priority patent/WO2015011396A1/fr
Priority to KR1020167004577A priority patent/KR102337149B1/ko
Priority to ES14758604.4T priority patent/ES2687475T3/es
Priority to US14/905,877 priority patent/US9765056B2/en
Priority to UAA201601398A priority patent/UA117020C2/uk
Priority to EA201600121A priority patent/EA028609B1/ru
Priority to NZ715847A priority patent/NZ715847A/en
Priority to TW103125162A priority patent/TW201504224A/zh
Priority to LTEP14758604.4T priority patent/LT3027602T/lt
Priority to HRP20181333TT priority patent/HRP20181333T1/hr
Priority to JP2016528587A priority patent/JP6458028B2/ja
Publication of FR3008978A1 publication Critical patent/FR3008978A1/fr
Priority to ZA2016/00415A priority patent/ZA201600415B/en
Priority to US15/676,154 priority patent/US10662173B2/en
Priority to CY20181100757T priority patent/CY1120475T1/el
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
FR1357277A 2013-07-23 2013-07-23 "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent" Withdrawn FR3008978A1 (fr)

Priority Applications (33)

Application Number Priority Date Filing Date Title
FR1357277A FR3008978A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
UY35653A UY35653A (es) 2013-07-23 2014-07-08 Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ARP140102679A AR099914A1 (es) 2013-07-23 2014-07-21 Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2016000900A MX364479B (es) 2013-07-23 2014-07-22 Nuevos derivados de indol y de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PT147586044T PT3027602T (pt) 2013-07-23 2014-07-22 Novos derivados de indole e de pirrolo, processo para a sua produção e composições farmacêuticas que os contêm
HK16106759.0A HK1218753A1 (zh) 2013-07-23 2014-07-22 新的吲哚和吡咯衍生物、它们的制备方法和含有它们的药物组合物
BR112016001333-6A BR112016001333B1 (pt) 2013-07-23 2014-07-22 Derivados de indol e pirrol e seu uso, processos para a produção dos mesmos, composições farmacêuticas e seu uso e combinações e seu uso
DK14758604.4T DK3027602T3 (en) 2013-07-23 2014-07-22 NEW INDO AND PYROL RELEASE DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
SI201430784T SI3027602T1 (en) 2013-07-23 2014-07-22 New indole and pyrrole derivatives, a process for their preparation and pharmaceutical compositions containing them
CA2917965A CA2917965C (fr) 2013-07-23 2014-07-22 Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PL14758604T PL3027602T3 (pl) 2013-07-23 2014-07-22 Nowe pochodne indolu i pirolu, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające
RU2016106002A RU2693404C2 (ru) 2013-07-23 2014-07-22 Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
RS20180839A RS57545B1 (sr) 2013-07-23 2014-07-22 Novi derivati indola i pirola, postupak njihove izrade i farmaceutske kompozicije koje ih sadrže
SG11201600004SA SG11201600004SA (en) 2013-07-23 2014-07-22 Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same
HUE14758604A HUE039507T2 (hu) 2013-07-23 2014-07-22 Új indol- és pirrolszármazékok, elõállítási eljárásuk és ezeket tartalmazó gyógyszerészeti készítmények
CN201480041559.7A CN105408321B (zh) 2013-07-23 2014-07-22 吲哚和吡咯衍生物、它们的制备方法和含有它们的药物组合物
AU2014294866A AU2014294866B2 (en) 2013-07-23 2014-07-22 Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same
EP16201228.0A EP3168217A1 (fr) 2013-07-23 2014-07-22 Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP14758604.4A EP3027602B1 (fr) 2013-07-23 2014-07-22 Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2014/051884 WO2015011396A1 (fr) 2013-07-23 2014-07-22 Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR1020167004577A KR102337149B1 (ko) 2013-07-23 2014-07-22 인돌 및 피롤의 유도체, 이의 제조 방법 및 이를 함유하는 약제 조성물
ES14758604.4T ES2687475T3 (es) 2013-07-23 2014-07-22 Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
US14/905,877 US9765056B2 (en) 2013-07-23 2014-07-22 Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
UAA201601398A UA117020C2 (uk) 2013-07-23 2014-07-22 Нові сполуки індолу і піролу, спосіб їх одержання і фармацевтичні композиції, що їх містять
EA201600121A EA028609B1 (ru) 2013-07-23 2014-07-22 Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
NZ715847A NZ715847A (en) 2013-07-23 2014-07-22 New indole and pyrrole derivatives useful as bcl-2 inhibitors, a process for their preparation and pharmaceutical compositions containing them
TW103125162A TW201504224A (zh) 2013-07-23 2014-07-22 新穎吲哚及吡咯化合物，其製備方法及含有其之醫藥組合物
LTEP14758604.4T LT3027602T (lt) 2013-07-23 2014-07-22 Nauji indolo ir pirolo dariniai, jų gamybos būdas ir juos turinčios farmacinės kompozicijos
HRP20181333TT HRP20181333T1 (hr) 2013-07-23 2014-07-22 Novi derivati indola i pirola, metoda za njihovu proizvodnju i farmaceutski pripravci koji ih sadržavaju
JP2016528587A JP6458028B2 (ja) 2013-07-23 2014-07-22 インドール及びピロールの新規な誘導体、その製造方法及びそれを含む医薬組成物
ZA2016/00415A ZA201600415B (en) 2013-07-23 2016-01-12 Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same
US15/676,154 US10662173B2 (en) 2013-07-23 2017-08-14 Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
CY20181100757T CY1120475T1 (el) 2013-07-23 2018-07-19 Νεα παραγωγα ινδολιου και πυρρολιου, μεθοδος για την παρασκευη αυτωn και φαρμακευτικες συνθεσεις που περιεχουν αυτα

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1357277A FR3008978A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"

Publications (1)

Publication Number Publication Date
FR3008978A1 true FR3008978A1 (fr) 2015-01-30

Family

ID=49911607

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1357277A Withdrawn FR3008978A1 (fr) 2013-07-23 2013-07-23 "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"

Country Status (31)

Country Link
US (2) US9765056B2 (https=)
EP (2) EP3027602B1 (https=)
JP (1) JP6458028B2 (https=)
KR (1) KR102337149B1 (https=)
CN (1) CN105408321B (https=)
AR (1) AR099914A1 (https=)
AU (1) AU2014294866B2 (https=)
BR (1) BR112016001333B1 (https=)
CA (1) CA2917965C (https=)
CY (1) CY1120475T1 (https=)
DK (1) DK3027602T3 (https=)
EA (1) EA028609B1 (https=)
ES (1) ES2687475T3 (https=)
FR (1) FR3008978A1 (https=)
HK (1) HK1218753A1 (https=)
HR (1) HRP20181333T1 (https=)
HU (1) HUE039507T2 (https=)
LT (1) LT3027602T (https=)
MX (1) MX364479B (https=)
NZ (1) NZ715847A (https=)
PL (1) PL3027602T3 (https=)
PT (1) PT3027602T (https=)
RS (1) RS57545B1 (https=)
RU (1) RU2693404C2 (https=)
SG (1) SG11201600004SA (https=)
SI (1) SI3027602T1 (https=)
TW (1) TW201504224A (https=)
UA (1) UA117020C2 (https=)
UY (1) UY35653A (https=)
WO (1) WO2015011396A1 (https=)
ZA (1) ZA201600415B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105237509A (zh) * 2015-11-20 2016-01-13 江苏瑞邦农药厂有限公司 一种2,2-二氟-1,3-苯并二恶茂的合成方法
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
AU2018208458B2 (en) * 2017-01-10 2020-07-16 ETH Zürich Cell-protective compounds and their use
TWI743346B (zh) 2017-03-31 2021-10-21 國立大學法人東京大學 諾羅病毒抗體
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN108409580A (zh) * 2018-02-01 2018-08-17 浙江工业大学 一种苄胺类化合物的合成方法
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
CN116997544A (zh) * 2021-03-24 2023-11-03 法国施维雅药厂 用于合成5-{5-氯-2-[(3s)-3-[(吗啉-4-基)甲基]-3,4-二氢异喹啉-2(1h)-羰基]苯基}-1,2-二甲基-1h-吡咯-3-甲酸衍生物的新方法及其在生产药物化合物中的应用
US20250387504A1 (en) 2022-05-20 2025-12-25 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
PY24103486A (es) 2023-11-22 2025-06-06 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023778A2 (en) * 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
WO2012162365A1 (en) * 2011-05-25 2012-11-29 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
WO2013110890A1 (fr) * 2012-01-24 2013-08-01 Les Laboratoires Servier Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2298832T3 (es) 2003-10-24 2008-05-16 Glaxo Group Limited Compuestos heterociclicos.
TW200533398A (en) * 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
GB0522908D0 (en) 2005-11-10 2005-12-21 Merck Sharp & Dohme Therapeutic agents
US9126980B2 (en) * 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
EP2794592A1 (en) * 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
BR112014015308A8 (pt) * 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com contrapartes de ligação
WO2013096051A1 (en) * 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
EP2794591A1 (en) * 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023778A2 (en) * 2004-08-20 2006-03-02 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
WO2012162365A1 (en) * 2011-05-25 2012-11-29 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
WO2013110890A1 (fr) * 2012-01-24 2013-08-01 Les Laboratoires Servier Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
LT3027602T (lt) 2018-07-25
AU2014294866B2 (en) 2018-09-27
RS57545B1 (sr) 2018-10-31
EA028609B1 (ru) 2017-12-29
SI3027602T1 (en) 2018-08-31
US10662173B2 (en) 2020-05-26
RU2016106002A (ru) 2017-08-30
BR112016001333A2 (https=) 2017-07-25
WO2015011396A1 (fr) 2015-01-29
US20170342051A1 (en) 2017-11-30
JP2016531108A (ja) 2016-10-06
BR112016001333B1 (pt) 2022-03-03
AU2014294866A1 (en) 2016-02-04
AR099914A1 (es) 2016-08-31
TW201504224A (zh) 2015-02-01
ES2687475T3 (es) 2018-10-25
CY1120475T1 (el) 2019-07-10
PT3027602T (pt) 2018-07-23
CN105408321A (zh) 2016-03-16
PL3027602T3 (pl) 2018-10-31
MX364479B (es) 2019-04-29
KR20160034384A (ko) 2016-03-29
RU2016106002A3 (https=) 2018-03-19
CN105408321B (zh) 2019-03-08
CA2917965A1 (fr) 2015-01-29
ZA201600415B (en) 2017-03-29
UY35653A (es) 2015-02-27
UA117020C2 (uk) 2018-06-11
EP3027602B1 (fr) 2018-06-13
EA201600121A1 (ru) 2016-07-29
US9765056B2 (en) 2017-09-19
HUE039507T2 (hu) 2019-01-28
US20160152599A1 (en) 2016-06-02
EP3027602A1 (fr) 2016-06-08
MX2016000900A (es) 2016-05-05
HK1218753A1 (zh) 2017-03-10
HRP20181333T1 (hr) 2018-10-19
SG11201600004SA (en) 2016-02-26
RU2693404C2 (ru) 2019-07-02
KR102337149B1 (ko) 2021-12-07
JP6458028B2 (ja) 2019-01-23
NZ715847A (en) 2019-06-28
DK3027602T3 (en) 2018-09-24
CA2917965C (fr) 2018-03-06
EP3168217A1 (fr) 2017-05-17

Similar Documents

Publication Publication Date Title
FR3008978A1 (fr) "nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
KR101714856B1 (ko) 치환된 피롤리딘-2-카복스아미드
FR3008975A1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP5424256B2 (ja) アザビシクロオクタンの誘導体、その製造方法及びそのジペプチジルペプチダーゼｉｖの阻害剤としての用途
EP3024833B1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EA009457B1 (ru) Бензимидазолоновые соединения, обладающие агонистической активностью в отношении 5-нтрецепторов
CN104341451A (zh) 新磷酸酯化合物、其制备方法及含有它们的药物组合物
JP2008526701A (ja) 有機化合物
JP2013515733A (ja) β−トリプターゼインヒビターとしてのインドリル−ピペリジニルベンジルアミン
FR3008977A1 (fr) Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA3198096A1 (en) Aryl derivatives for treating trpm3 mediated disorders
CA2961033A1 (en) Heterocyclic compound
JP2009503050A (ja) ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物
JP2007529474A (ja) 高血圧の処置のためのレニン阻害剤としての５−アミノ−４−ヒドロキシ−７−（１ｈ−インドールメチル）−８−メチルノンアミド誘導体
ES2866324T3 (es) Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria
EA021053B1 (ru) (ФЕНИЛ)АМИДЫ 7-(ПИПЕРАЗИН-1-ИЛМЕТИЛ)-1H-ИНДОЛ-2-КАРБОНОВОЙ КИСЛОТЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ МАР-КИНАЗЫ p38 ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ДЫХАТЕЛЬНЫХ ПУТЕЙ
FR2933701A1 (fr) Derives anticancereux, leur preparation et leur application en therapeutique
KR20070022753A (ko) 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도
OA16962A (fr) Nouveaux dérivés phosphates, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20200306